Article Text

Download PDFPDF

C-reactive protein in patients with COPD, control smokers and non-smokers
  1. V M Pinto-Plata1,
  2. H Müllerova2,
  3. J F Toso3,
  4. M Feudjo-Tepie2,
  5. J B Soriano2,
  6. R S Vessey3,
  7. B R Celli1
  1. 1Pulmonary and Critical Care Division, Caritas St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA
  2. 2GlaxoSmithKline R&D, Worldwide Epidemiology Department, London, UK
  3. 3GlaxoSmithKline R&D, Discovery Medicine Department, King of Prussia, PA, UK
  1. Correspondence to:
    Dr V M Pinto-Plata


Background: Patients with chronic obstructive pulmonary disease (COPD) have raised serum levels of C reactive protein (CRP). This may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as concomitant ischaemic heart disease (IHD) or smoking status. The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels.

Methods: Cross sectional analyses comparing cohorts of 88 patients with COPD, 33 smokers (S), and 38 non-smoker (NS) controls were performed. Clinical assessments included a complete medical history, pulmonary function, 6 minute walk test (6MWT), cardiopulmonary exercise test, and high sensitivity serum CRP measurements.

Results: Serum CRP levels were significantly higher in patients with COPD (5.03 (1.51) mg/l) than in controls (adjusted odds ratio 9.51; 95% confidence interval 2.97 to 30.45) but were similar in the two control groups (S: 2.02 (1.04) mg/l; NS: 2.24 (1.04) mg/l). There was no clinical or exercise evidence of unstable IHD in any of the subjects. CRP levels were lower in COPD patients treated with ICS than in those not treated (3.7 (3.0) mg/l v 6.3 (3.6) mg/l); this association was confirmed in an adjusted regression model (p<0.05).

Conclusion: CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS. CRP may be a systemic marker of the inflammatory process that occurs in patients with COPD.

  • COPD, chronic obstructive pulmonary disease
  • CRP, C-reactive protein
  • FEV1, forced expiratory volume in 1 second
  • FRC, functional residual capacity
  • FVC, forced vital capacity
  • ICS, inhaled corticosteroids
  • IHD, ischaemic heart disease
  • 6MWT, 6 minute walk test
  • TLC, total lung capacity
  • Tlco, carbon monoxide transfer factor
  • o2peak, peak oxygen consumption
  • C-reactive protein
  • chronic obstructive pulmonary disease
  • ischaemic heart disease
  • smoking
  • inhaled corticosteroids
  • systemic inflammation
  • exercise capacity

Statistics from


  • Published Online First 2 September 2005

  • This work was supported by a grant from GlaxoSmithKline.

  • Competing interests: none declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    Wisia Wedzicha